---
reference_id: "PMID:31263285"
title: Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.
authors:
- Zeitler B
- Froelich S
- Marlen K
- Shivak DA
- Yu Q
- Li D
- Pearl JR
- Miller JC
- Zhang L
- Paschon DE
- Hinkley SJ
- Ankoudinova I
- Lam S
- Guschin D
- Kopan L
- Cherone JM
- Nguyen HB
- Qiao G
- Ataei Y
- Mendel MC
- Amora R
- Surosky R
- Laganiere J
- Vu BJ
- Narayanan A
- Sedaghat Y
- Tillack K
- Thiede C
- Gärtner A
- Kwak S
- Bard J
- Mrzljak L
- Park L
- Heikkinen T
- Lehtimäki KK
- Svedberg MM
- Häggkvist J
- Tari L
- Tóth M
- Varrone A
- Halldin C
- Kudwa AE
- Ramboz S
- Day M
- Kondapalli J
- Surmeier DJ
- Urnov FD
- Gregory PD
- Rebar EJ
- Muñoz-Sanjuán I
- Zhang HS
journal: Nat Med
year: '2019'
doi: 10.1038/s41591-019-0478-3
content_type: abstract_only
---

# Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.
**Authors:** Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L, Paschon DE, Hinkley SJ, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone JM, Nguyen HB, Qiao G, Ataei Y, Mendel MC, Amora R, Surosky R, Laganiere J, Vu BJ, Narayanan A, Sedaghat Y, Tillack K, Thiede C, Gärtner A, Kwak S, Bard J, Mrzljak L, Park L, Heikkinen T, Lehtimäki KK, Svedberg MM, Häggkvist J, Tari L, Tóth M, Varrone A, Halldin C, Kudwa AE, Ramboz S, Day M, Kondapalli J, Surmeier DJ, Urnov FD, Gregory PD, Rebar EJ, Muñoz-Sanjuán I, Zhang HS
**Journal:** Nat Med (2019)
**DOI:** [10.1038/s41591-019-0478-3](https://doi.org/10.1038/s41591-019-0478-3)

## Content

1. Nat Med. 2019 Jul;25(7):1131-1142. doi: 10.1038/s41591-019-0478-3. Epub 2019
Jul  1.

Allele-selective transcriptional repression of mutant HTT for the treatment of 
Huntington's disease.

Zeitler B(1), Froelich S(2), Marlen K(2), Shivak DA(2), Yu Q(2), Li D(2), Pearl 
JR(2), Miller JC(2), Zhang L(2), Paschon DE(2), Hinkley SJ(2), Ankoudinova I(2), 
Lam S(2), Guschin D(2)(3), Kopan L(2), Cherone JM(2), Nguyen HB(2), Qiao G(2), 
Ataei Y(2), Mendel MC(2), Amora R(2), Surosky R(2), Laganiere J(2)(4), Vu BJ(2), 
Narayanan A(2), Sedaghat Y(5), Tillack K(5), Thiede C(5), Gärtner A(5), Kwak 
S(6), Bard J(6), Mrzljak L(6), Park L(6), Heikkinen T(7), Lehtimäki KK(7), 
Svedberg MM(8), Häggkvist J(8), Tari L(8), Tóth M(8), Varrone A(8), Halldin 
C(8), Kudwa AE(9), Ramboz S(9), Day M(10), Kondapalli J(10), Surmeier DJ(10), 
Urnov FD(2)(11), Gregory PD(2), Rebar EJ(2), Muñoz-Sanjuán I(12), Zhang 
HS(2)(13).

Author information:
(1)Sangamo Therapeutics, Inc., Richmond, CA, USA. bzeitler@sangamo.com.
(2)Sangamo Therapeutics, Inc., Richmond, CA, USA.
(3)Laboratory of Intracellular Signalling, Moscow Institute of Physics and 
Technology, Dolgoprudnyi, Russian Federation.
(4)Medical Affairs and Innovation, Hema-Quebec, Quebec City, Quebec, Canada.
(5)Evotec AG, Hamburg, Germany.
(6)CHDI Management/CHDI Foundation, Los Angeles, CA, USA.
(7)Charles River Discovery Services, Kuopio, Finland.
(8)Department of Clinical Neuroscience, Center for Psychiatry Research, 
Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
(9)Psychogenics, Inc., Paramus, NJ, USA.
(10)Department of Physiology, Feinberg School of Medicine, Northwestern 
University, Chicago, IL, USA.
(11)Innovative Genomics Institute, Berkeley, CA, USA.
(12)CHDI Management/CHDI Foundation, Los Angeles, CA, USA. 
ignacio.munoz@chdifoundation.org.
(13)Applied StemCell, Inc., Milpitas, CA, USA.

Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder 
caused by a CAG trinucleotide expansion in the huntingtin gene (HTT), which 
codes for the pathologic mutant HTT (mHTT) protein. Since normal HTT is thought 
to be important for brain function, we engineered zinc finger protein 
transcription factors (ZFP-TFs) to target the pathogenic CAG repeat and 
selectively lower mHTT as a therapeutic strategy. Using patient-derived 
fibroblasts and neurons, we demonstrate that ZFP-TFs selectively repress >99% of 
HD-causing alleles over a wide dose range while preserving expression of >86% of 
normal alleles. Other CAG-containing genes are minimally affected, and virally 
delivered ZFP-TFs are active and well tolerated in HD neurons beyond 100 days in 
culture and for at least nine months in the mouse brain. Using three HD mouse 
models, we demonstrate improvements in a range of molecular, histopathological, 
electrophysiological and functional endpoints. Our findings support the 
continued development of an allele-selective ZFP-TF for the treatment of HD.

DOI: 10.1038/s41591-019-0478-3
PMID: 31263285 [Indexed for MEDLINE]